Atrial fibrillation affects up to 70% of patients with ATTR-CM—but how does it impact treatment outcomes?

Dr. Brett Sperry and Dr. C. Michael Gibson discuss new findings showing that acoramidis delivered consistent clinical benefits regardless of baseline atrial fibrillation status and was associated with fewer new or worsening AF events.

Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.